[QODLink]
Europe
Diabetes drug comes under scrutiny
European drugs watchdog discusses safety of Avandia after British regulators raise concerns over heart risks.
Last Modified: 08 Sep 2010 16:22 GMT
The Food and Drug Administration in the US has placed Avandia under scrutiny since 2007  [EPA]

A European drugs watchdog is holding a special meeting to review the safety of Avandia, a widely-used diabetes drug, amid calls for it to be withdrawn because of concerns about heart risks.

The European Medicines Agency (EMA) met in London, the British capital, on Wednesday, two days after UK drug regulators called for product to be pulled from the market.

It said the extraordinary session was necessary because of the complexity of the data being assessed, but will not decide on the drug's future until its next scheduled meeting in late September.

The British Medical Journal (BMJ) and some leading doctors have criticised the response, calling for Avandia to be pulled off the market immediately - saying it should never have been licensed in the first place.

'Multiple problems'

On Monday, Britain's Medicines and Healthcare products Regulatory Agency (MHRA), said Avandia should be pulled from the UK market because of concerns that the drug could increase the risk of heart attacks.

They said an independent panel of experts had advised that the risks of the product outweighed its benefits, and that the drug should no longer be sold in Britain.

The body said it had sent a letter to doctors in July advising them to consider alternative treatments.

Avandia, made by pharmaceutical company Glaxo Smith Kline (GSK), was approved by the EMA in 2000 to help lower blood sugar levels in patients with Type 2 diabetes.

GSK has maintained that its extensive research involving over 50,000 patients has shown that Avandia does not increase the overall risk of heart attack, stroke or death compared to other diabetes drugs.

"We continue to believe that Avandia is safe and effective when it is prescribed appropriately," the company said in a statement.

But the British Medical Journal was critical of both GSK's research methods and the European approval process, outlining what were described as multiple problems associated with Avandia's safety in a report published on Monday.

In the US, the Food and Drug Administration (FDA) has placed Avandia under scrutiny since 2007, when a study suggested that patients taking the drug were 43 per cent more likely to experience a heart attack than those taking other diabetes drugs or no diabetes medication at all.

Source:
Agencies
Topics in this article
Country
City
Organisation
Featured on Al Jazeera
An innovative rehabilitation programme offers Danish fighters in Syria an escape route and help without prosecution.
Street tension between radical Muslims and Holland's hard right rises, as Islamic State anxiety grows.
Take an immersive look at the challenges facing the war-torn country as US troops begin their withdrawal.
Ministers and MPs caught on camera sleeping through important speeches have sparked criticism that they are not working.
Featured
About 500,000 participated around the globe in the Peoples Climate March, and Al Jazeera spoke to some in New York.
Separatist movements in Spain, Belgium and Italy may face headwinds following Scotland's decision to stay in the UK.
A fishing trawler carrying 500 migrants across the Mediterranean was rammed by another boat, causing hundreds to drown.
Anti-immigration Sweden Democrats party - with roots in the neo-Nazi movement - recently won 12.9 percent of the vote.
Palestinian doctor who lost three daughters in previous Gaza war is fighting to bring 100 wounded kids to Canada.